Physician profile
Yaroslav Kushnir
NPI 1730274176
$2,241.42
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $738 · 2021: $950 · 2022: $156.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $697.61 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $678.15 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $440.94 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118.84 | 2021 | |
| Noven Therapeutics, LLC | $77.33 | 2020-2021 | |
| Alkermes, INC. | $74.12 | 2019-2021 | |
| Almatica Pharma LLC | $44.21 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $36.67 | 2019 | |
| Neurocrine Biosciences, INC. | $30.88 | 2022 | |
| Merck Sharp & Dohme LLC | $19.45 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.09 | 2019 | |
| Indivior INC. | $11.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaroslav Kushnir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.